InvestorsHub Logo
Followers 139
Posts 5289
Boards Moderated 0
Alias Born 03/01/2013

Re: None

Monday, 09/28/2015 12:10:57 PM

Monday, September 28, 2015 12:10:57 PM

Post# of 10489
Positive results as expected yet PPS goes down: GALE dejavu all over again: it's gotta stop some time when investors ignore the shorts:

(RTTNews.com) - Galena Biopharma, Inc. (GALE) announced that data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial was presented at the European Cancer Congress 2015 in Vienna, Austria. GALE-301 is Galena's cancer immunotherapy that consists of a peptide derived from Folate Binding Protein.

"This one-year data from our GALE-301 trial is extremely encouraging as it has established the optimal dose while demonstrating clear signs of improvement in the disease free status of women with endometrial and ovarian cancer in the 1000 mcg cohort," said Mark Schwartz, President and CEO.

GALE-301 is combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor and administered via intradermal injection for the prevention of recurrence in ovarian and endometrial cancers.

Read more: http://www.nasdaq.com/article/galena-biopharma-reports-positive-gale301-phase-2a-trial-data--quick-facts-20150928-00327#ixzz3n3AuUlm2


Opened @$1.72 after declining all way on positive expectations and here it is 3 hrs. into trading: totally counter-intuitive, classic biotech shorting and a shame;

but there WILL be a catalyst that will vindicate longs...eventually.


GALE : NASDAQ GALENA BIOPHARMA INC
Last: 1.6201
Change: -0.0299 (-1.81%)
Bid/Size: 1.62/160
Ask/Size: 1.63/57
Volume: 970,862
52 week high: 2.39
52 week low: 1.10
As of 12:22:57 PM ET 9/28/2015

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.